Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long Term Follow-up Protocol to Evaluate the Safety and Survival of Autologous CD34+ Hematopoietic Progenitor Cells Transduced With an Anti-HIV-1 Ribozyme (OZ1) in Patients With HIV-1 Infection

NCT01177059 is registered in ClinicalTrials.gov with Janssen-Cilag Pty Ltd as lead sponsor.

NCT NCT01177059
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01177059 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long Term Follow-up Protocol to Evaluate the Safety and Survival of Autologous CD34+ Hematopoietic Progenitor Cells Transduced With an Anti-HIV-1 Ribozyme (OZ1) in Patients With HIV-1 Infection
Lead sponsor
Janssen-Cilag Pty Ltd
Phase
Phase 2
Overall status
Completed
Start date
December 6, 2004
Completion date
November 30, 2017
Enrollment
68 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1